A focus on PD-L1 in human melanoma

Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013-02, Vol.19 (3), p.514-516
Hauptverfasser:	Hersey, Peter, Gallagher, Stuart
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - metabolism Drug Resistance, Neoplasm Humans Melanoma - metabolism Mitogen-Activated Protein Kinase Kinases - metabolism Phosphatidylinositol 3-Kinases - metabolism Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy?
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-12-3312